Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed 11 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or metastatic head and neck cancer.

Timeline

Start: 2000-09
Primary completion: 2004-07
Completion: 2004-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	fenretinide	Small molecule	900 mg/m2	Oral

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Summary

Timeline

Drugs

Indications